1,721,249 research outputs found
Referral patterns, prognostic models and treatment in soft tissue sarcomas
Full text linkSoft tissue sarcomas are cancers of supporting tissues in the body. The incidence is low, but rises, with 750 new patients in 2017 in the Netherlands. Because of low prevalence and heterogeneous clinical behavior, sarcoma patients should be referred to one of the sarcoma centers for consultation and/or treatment. Recognizing sarcomas is difficult and leads to considerable delays in making the diagnosis of the patient and doctor. An adequate training of doctors and an efficient diagnostic process in the hospital are of vital importance. Individualized oncology treatment is on the rise. Proliferation markers can contribute to differentiating low and high risk sarcoma patients for whom additional therapy - chemotherapy, radiation and/or systemic therapy - is necessary to reduce the chance of recurrence and/or improve survival. For locally advanced sarcomas of the extremities, combined therapy with isolated regional perfusion with chemotherapy and/or radiation is used to reduce the vital tumor and enable local resection, thereby avoiding amputation in approximately 85% of patients. Angiosarcomas and desmoid-type fibromatosis are rare types of sarcomas that require special surgical approaches. Surgery with large margins is the cornerstone for local aggressively growing and metastatic angiosarcomas. In the only locally infiltrating desmoid-type fibromatosis tumors, smaller surgical margins suffice and observation with intensive follow-up seems justified. The optimization in the treatment of soft tissue sarcomas has been achieved in recent years through more insight into the biological behavior, centralization and the personalized treatment of these rare tumors
Difficult journeys in sarcoma care; socioeconomic disparity added to the multiple challenges of a rare tumor diagnosis
No full textCanceröverlevnaden på väg uppåt i Danmark efter 3-punktsplan Snabb utredning vid misstänkt cancersjukdom är en grund.
Full text linkTimely treatment initiation; a reminder about effort to reduce system-related lead times
No full text
Vårdskadeomväntetider i cancervården är en patientsäkerhetsfråga : Risken för cancerrelaterad morbiditet och sämre överlevnad behöver uppmärksammas
Full text linkWaiting times in cancer care is a patient safety risk that needs increased attention. Mechanisms and effects need to be clarified, waiting time statistics should be openly presented and evidence-based strategies should be implemented. Cancer patient pathways are implemented in Sweden during 2015–2018 and are expected to reduce waiting times for some patient groups, but cannot be expected to present a complete solution to the waiting time problem. Strategic work on waiting times requires knowledge about the different symptom profiles in various cancer types, understanding of the impact from waiting times in different cancer types and increased knowledge about the mechanisms in the health care system that cause waiting times
- …
